Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families

被引:25
作者
Yakobson, E
Shemesh, P
Azizi, E
Winkler, E
Lassam, N
Hogg, D
Brookes, S
Peters, G
Lotem, M
Zlotogorski, A
Landau, M
Safro, M
Shafir, R
Friedman, E
Peretz, H [1 ]
机构
[1] Tel Aviv Univ, Sourasky Med Ctr, Lab Clin Biochem, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sourasky Med Ctr, Dept Plast Surg, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Sourasky Med Ctr, Dept Dermatol, IL-69978 Tel Aviv, Israel
[4] Chaim Sheba Med Ctr, Dept Dermatol, IL-52621 Tel Hashomer, Israel
[5] Chaim Sheba Med Ctr, Dept Plast Surg, IL-52621 Tel Hashomer, Israel
[6] Chaim Sheba Med Ctr, Susanne Levy Geatner Oncogenet Unit, IL-52621 Tel Hashomer, Israel
[7] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Dermatol, Jerusalem, Israel
[8] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel
[9] Univ Toronto, Dept Med, Toronto, ON, Canada
[10] Imperial Canc Res Fund, London WC2A 3PX, England
关键词
p16; CDKN2A; germline mutations; Israeli Jewish melanoma families;
D O I
10.1038/sj.ejhg.5200505
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations in the p16 (CDKN2A) tumour suppressor gene have been linked to inherited predisposition to malignant melanoma (MM). Variable frequencies of p16 germline mutations were reported in different collections of melanoma families but it can be as high as 50%. Here we describe the results of p16 mutation screening in 30 melanoma kindreds in Israel. The entire coding region of the p16 gene, including exons 1, 2 and 3, flanking exon/intron junctions, and a portion of the 3' untranslated (UTR) region of the gene were examined by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing. Two p16 germline mutations were identified: G101W, which has been previously observed in a number of melanoma kindreds, and G122V, a novel missense mutation. Thus, the frequency of mutations identified in this collection of Israeli families was 7%. Functional analysis Indicated that the novel G122V variant retained some capacity to interact with cyclin dependent kinases (CDKs) in vitro, yet it was significantly impaired in its ability to cause a G1 cell cycle arrest in human diploid fibroblasts. This partial loss of function is consistent with the predicted impact of G122V substitution on the 3-dimensional structure of the p16 protein.
引用
收藏
页码:590 / 596
页数:7
相关论文
共 36 条
  • [1] The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim
    Bar-Sade, RB
    Kruglikova, A
    Modan, B
    Gak, E
    Hirsh-Yechezkel, G
    Theodor, L
    Novikov, I
    Gershoni-Baruch, R
    Risel, S
    Papa, MZ
    Ben-Baruch, G
    Friedman, E
    [J]. HUMAN MOLECULAR GENETICS, 1998, 7 (05) : 801 - 805
  • [2] The retinoblastoma protein pathway in cell cycle control and cancer
    Bartek, J
    Bartkova, J
    Lukas, J
    [J]. EXPERIMENTAL CELL RESEARCH, 1997, 237 (01) : 1 - 6
  • [3] FAMILY STUDIES IN MELANOMA - IDENTIFICATION OF THE ATYPICAL MOLE SYNDROME (AMS) PHENOTYPE
    BISHOP, JAN
    BATAILLE, V
    PINNEY, E
    BISHOP, DT
    [J]. MELANOMA RESEARCH, 1994, 4 (04) : 199 - 206
  • [4] Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations
    Bishop, JAN
    Wachsmuth, RC
    Harland, M
    Bataille, V
    Pinney, E
    Mack, P
    Baglietto, L
    Cuzick, J
    Bishop, DT
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) : 28 - 33
  • [5] Borg A, 1996, CANCER RES, V56, P2497
  • [6] HUNDREDS OF ANKYRIN-LIKE REPEATS IN FUNCTIONALLY DIVERSE PROTEINS - MOBILE MODULES THAT CROSS PHYLA HORIZONTALLY
    BORK, P
    [J]. PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1993, 17 (04): : 363 - 374
  • [7] Ribbons
    Carson, M
    [J]. MACROMOLECULAR CRYSTALLOGRAPHY, PT B, 1997, 277 : 493 - 505
  • [8] Ciotti P, 1996, NEW ENGL J MED, V334, P469
  • [9] The CDKN2A (p16) gene and human cancer
    Foulkes, WD
    Flanders, TY
    Pollock, PM
    Hayward, NK
    [J]. MOLECULAR MEDICINE, 1997, 3 (01) : 5 - 20
  • [10] Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO